Ready Med: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of Ready Med’s website, https://readymednow.com, FDA Establishment Identifier (FEI) 3044868483, in May 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products. As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.

1. 1

   “1. The compounded semaglutide and tirzepatide products displayed on your website identify “Ready Med” or “Ready Med Medical Weight Loss Center” on the pictured label, suggesting Ready Med is the compounder of those drugs when in fact it is not.”

2. 2

   “2. The following claims concerning compounded semaglutide and tirzepatide products appear on your website: “The same active ingredient in Mounjaro® and Zepbound™” “The same active ingredient in Ozempic® and Rybelsus®” Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

readymednow.com returned a live site on 2026-08-09 headed "Ready Med", printing the same Clearwater street address and readymedstaff@gmail.com contact that appear on the FDA letter, and advertising a first-month weight-management offer with a $99 consultation and a booking flow — an operating clinic.

The detail that repays attention is the pairing of Ozempic® with Rybelsus®. Those two are not interchangeable in the way the phrase "the same active ingredient" suggests: one is a weekly injection and the other a daily tablet, and the dose, the absorption and the approved use differ accordingly. A compounded injection cannot be equivalent to both, so a line claiming kinship with each is borrowing credibility from products that are not even equivalent to one another. FDA's own response goes further than the softer letters in this roster — it says the claims represent approval rather than merely imply it. The label finding is the other unusual piece: the vials carried two different versions of the seller's name, and neither was the compounder's. Reading the two findings together, a buyer was told who made the drug (wrongly, in two forms) and what it was equivalent to (in a comparison that does not hold), which between them cover most of what a person would check before paying. The letter says nothing about whether the medication is safe or what it should cost.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Ready Med failed to respond.